CPRX
Catalyst Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.49
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 597.0M | 589.0M | 491.7M | 398.2M | 214.2M |
| Cost of Revenue | 105.5M | 87.3M | 68.8M | 52.0M | 34.4M |
| Gross Profit | 491.4M | 501.7M | 422.9M | 346.2M | 179.8M |
| Operating Expenses | |||||
| R&D Expense | 11.5M | 12.7M | 12.6M | 93.2M | 19.8M |
| SG&A Expense | 196.2M | 193.8M | 177.7M | 133.7M | 57.1M |
| General & Admin Expense | 106.6M | 71.5M | 167.7M | 47.0M | 53.8M |
| Selling & Marketing Expense | 40.2M | 122.2M | 10.0M | 86.7M | 3.3M |
| Other Expenses | 16.2M | 37.5M | 37.4M | 32.6M | 1.1M |
| Total Operating Expenses | 223.8M | 244.0M | 227.8M | 259.4M | 78.0M |
| Cost and Expenses | 329.3M | 331.2M | 296.6M | 311.4M | 112.4M |
| Operating Income (EBIT) | 267.6M | 257.8M | 195.1M | 86.8M | 101.8M |
| Non-Operating | |||||
| Interest Income | 12.2M | — | 16.1M | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 12.2M | — | 16.1M | — | — |
| Other Non-Op Income/Expense | 28.8M | 25.7M | 21.1M | 7.7M | 2.9M |
| Non-Operating Income (excl Interest) | (28.8M) | (25.7M) | (21.1M) | (7.7M) | (2.9M) |
| EBT (Pre-Tax Income) | 296.5M | 283.5M | 216.3M | 94.5M | 104.7M |
| Income Tax Expense | 75.1M | 69.2M | 52.4M | 23.1M | 21.6M |
| Bottom Line | |||||
| Net Income | 221.3M | 214.3M | 163.9M | 71.4M | 83.1M |
| Earnings from Cont. Ops | 221.3M | 214.3M | 163.9M | 71.4M | 83.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 221.3M | 214.3M | 163.9M | 71.4M | 83.1M |
| Per Share | |||||
| Basic EPS | $1.80 | $1.75 | $1.38 | $0.67 | $0.80 |
| Diluted EPS | $1.73 | $1.68 | $1.31 | $0.63 | $0.75 |
| Revenue Per Share | $4.88 | $4.82 | $4.15 | $3.75 | $2.07 |
| Shares | |||||
| Basic Shares Outstanding | 122.3M | 122.3M | 118.5M | 106.3M | 103.4M |
| Diluted Shares Outstanding | 126.9M | 127.3M | 124.9M | 113.8M | 111.4M |
| Profitability Metrics | |||||
| EBITDA | 334.7M | 321.4M | 254.0M | 127.4M | 106.0M |
| D&A | 38.3M | 37.9M | 37.8M | 32.9M | 1.2M |
| EBIT | 296.5M | 283.5M | 216.3M | 94.5M | 104.7M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026